A recent study shows that Eribulin, an anti-cancer drug used to treat breast cancer and liposarcoma, triggers cancer cell death via the STING1-dependent signaling axis (Fermaintt et al., 2021; Takahashi-Ruiz et al., 2022), indicating its role as a cell-death-promoting factor. This evidence concerns the gene STING1 and breast carcinoma.